Brexpiprazole: A Review in Schizophrenia
详细信息 查看全文
- 作者：Karly P. Garnock-Jones
- 刊名：CNS Drugs
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：30
- 期：4
- 页码：335-342
- 全文大小：531 KB
- 刊物主题：Neurology; Psychopharmacology; Pharmacotherapy; Neurosciences; Psychiatry;
- 出版者：Springer International Publishing
- ISSN：1179-1934
- 卷排序：30
文摘
Oral brexpiprazole (Rexulti®) is a partial dopamine D2 agonist, which also has activity at several other receptors. This article reviews the pharmacological properties of brexpiprazole and its clinical efficacy and tolerability in patients with schizophrenia; its use in patients with major depressive disorder is beyond the scope of this review. Brexpiprazole 2–4 mg/day was generally effective in short-term, phase III studies at improving Positive and Negative Symptom Scale scores and other schizophrenia symptoms in patients with acute schizophrenia. Moreover, maintenance treatment with brexpiprazole 1–4 mg/day was associated with a significantly longer time to exacerbation of disease or impending relapse than placebo. The drug was well tolerated in clinical trials, with most serious adverse events in the short term being associated with the underlying disorder. Overall, oral brexpiprazole is a useful treatment option for the treatment of patients with schizophrenia.The manuscript was reviewed by: M. Shumway, Department of Psychiatry, University of California, San Francisco/San Francisco General Hospital, San Francisco, CA, USA; J. Volavka, Department of Psychiatry, New York University School of Medicine, Big Sky, MT, USA.